DAWN — Day One Biopharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $2.22bn
- $1.77bn
- $158.18m
Annual cashflow statement for Day One Biopharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -72.8 | -142 | -189 | -95.5 | -107 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 21.5 | 25.7 | 32.6 | -10.7 | 29 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.69 | 6.56 | 9.42 | 26.5 | -28.9 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -48.5 | -110 | -147 | -78.1 | -104 |
| Capital Expenditures | 0 | -0.026 | -0.224 | -19.3 | -3.82 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -8 | -255 | 129 | -212 | 178 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -8 | -255 | 128 | -231 | 175 |
| Financing Cash Flow Items | 0 | — | — | 178 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 297 | 166 | 164 | 203 | 1.22 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 241 | -199 | 146 | -106 | 72.1 |